Ivonescimab plus radiofrequency ablation for advanced tumors after PD-1 therapy
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of a drug called ivonescimab (which targets PD-1 and VEGF) and a procedure that uses heat to destroy tumors (radiofrequency ablation). It is for people with advanced cancer whose previous PD-1 treatment stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have advanced cancer that has been confirmed by a biopsy or imaging.
- You must have at least one tumor that can be measured on a CT scan and another tumor that can be treated with radiofrequency ablation.
- Your blood counts, liver, and kidney function must be within certain limits.
- You must be willing to use effective birth control during the study and for 120 days after.
- You must not have serious uncontrolled medical conditions like poorly controlled blood pressure, heart disease, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Hear when a new Multiple Advanced Tumors After PD-1 Therapy Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.